Clostridium is a gram-positive bacteria which belongs to phylum Firmicutes. It’s an obligate anaerobe capable of producing endospores. Clostridium botulinium, Clostridium difficle, Clostridium perfringens, Clostridium tetani and Clostridium sordellii are the different species of clostridium responsible for diseases in humans. Clostridium tetani is the etiological agent of tetanus, Clostridium botulinum is the etiological agent of botulism. Clostridium perfringes is one of the etiological agents of gas gangrene. Clostridium sortellii is capable of causing pneumonia, endocarditis, arthritis, peritonitis, and myonecrosis. Clostridium difficle is the etiological agent of diarrhea.
The global clostridium diagnostics market can be segmented as follows:
- Fluorescent-Antibody Assays
- Poloymerase Chain Reactions
The clostridium diagnostics market is driven by the rising population, growing awareness about clostridium related disorders and technological developments in diagnostics equipment such as artificial intelligence and automation.
Prevalence of clostridium and its different species was observed more in North America and Europe compared to Asia Pacific and Rest of the World. Thus, North America currently leads this market followed by Europe. Asia-Pacific is a growing market for clostridium diagnostics with rapid economic development, growing awareness about critical diseases and their prevention and countries with highest population in the world such as China and India with mediocre or developing healthcare infrastructure. Brazil and the Gulf countries are considered to be driving the clostridium diagnostics market in Rest of the World.
Some of the major companies contributing to the global clostridium diagnostics market include Abbott Laboratories, Beckman Coulter, Inc., Biochem Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Olympus Corporation, F. Hoffmann-La Roche Ltd and Siemens.